Literature DB >> 7116738

Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics.

E Wåhlin-Boll, L O Almér, A Melander.   

Abstract

The pharmacokinetics of glipizide were studied in 6 type 2 diabetics following single dose intravenous administration of Img, and oral administration of 2.5 mg as a solution, a 2.5 mg tablet and a 5 mg tablet. The serum concentrations of the drug were measured by high pressure liquid chromatography. Glipizide showed a rapid distribution fitting a 2-compartment model. The distribution volume at assumed distribution equilibrium was small (10L), and the elimination half-life was short (2 to 4 hours). Gastrointestinal bioavailability was 100%. In one patient, glipizide absorption from tablets was retarded due to delayed tablet disintegration and drug dissolution. Each dose of glipizide reduced blood glucose levels rapidly in all patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7116738     DOI: 10.2165/00003088-198207040-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  6 in total

1.  An improved glucose-oxidase method for determining blood, C.S.F. and urine glucose levels.

Authors:  V MARKS
Journal:  Clin Chim Acta       Date:  1959-05       Impact factor: 3.786

2.  Interaction of glipizide with human serum albumin.

Authors:  M J Crooks; K F Brown
Journal:  Biochem Pharmacol       Date:  1975-01-15       Impact factor: 5.858

3.  High-performance liquid chromatographic determination of glipizide and some other sulfonylurea drugs in serum.

Authors:  E Wåhlin-Boll; A Melander
Journal:  J Chromatogr       Date:  1979-12-01

4.  Potentiation of insulin secretion to nonglucose stimuli in normal man by tolbutamide.

Authors:  M A Pfeifer; J B Halter; R Graf; D Porte
Journal:  Diabetes       Date:  1980-05       Impact factor: 9.461

5.  Comparison of the pharmacokinetics of glipizide and glibenclamide in man.

Authors:  L Balant; J Fabre; G R Zahnd
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

Review 6.  Glipizide: a review of its pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-11       Impact factor: 9.546

  6 in total
  16 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

Review 3.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide.

Authors:  K T Kivistö; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

6.  The influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycaemia.

Authors:  P O Bitzén; A Melander; B Scherstén; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers.

Authors:  Sanju Dhawan; Bhupinder Singh; Santosh Kumar Garg; Debasish Hota; Radharaman Jiban Dash; Anil Kumar Singla; Vivek Ranjan Sinha
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Lack of primary effect of sulphonylurea (glipizide) on plasma lipoproteins and insulin action in former type 2 diabetics with attenuated insulin secretion.

Authors:  G Sartor; D Ursing; P Nilsson-Ehle; E Wåhlin-Boll; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

10.  Therapeutic equivalence of once- and thrice-daily glipizide.

Authors:  E Wåhlin-Boll; L Groop; S Karhumaa; P H Groop; K J Tötterman; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.